Neurology:独立于传统血管危险因素,循环白细胞介素-6(IL-6)水平与发生缺血性卒中长期风险呈正线性相关!

2022-01-16 Naomi MedSci原创

近日,研究人员利用已发表/未发表研究进行系统回顾和荟萃分析,探索基于人群的前瞻性队列研究中循环IL-6水平与缺血性卒中发病风险的关系,证实了较高的IL-6水平与较高的发生缺血性卒中长期风险呈线性关系。

      卒中是世界范围内成年人残疾和死亡的主要原因。确定卒中的危险因素对于制定有效的一级和二级预防策略非常重要。炎症最近作为降低缺血性卒卒中险的一个潜在目标引起了人们的关注。来自大规模试验的数据提供了部分证据,证明抗炎治疗可以降低心血管疾病的风险。尽管如此,这些试验测试了心血管事件终点和关于专门用于预防卒中的抗炎方法的有效证据很少。

      开发有效的抗炎治疗途径以预防卒中将需要确定与卒中发病相关的关键炎症介质。虽然有大量文献表明炎症的一般标志物C-反应蛋白(CRP)水平与卒中的相关性,但关于其他炎症细胞因子的数据有限。来自人类遗传学研究的数据表明,促炎症细胞因子白细胞介素-6(IL-6)在血管疾病中的潜在致病作用,有望成为新药物靶点。

      明确循环IL-6水平与缺血性卒中之间关联和相关机制,将推动IL-6信号的抗炎治疗的进一步迈进。虽然前瞻性队列研究已确定循环中IL-6水平与冠状动脉疾病风险之间存在明显的相关性,但表明与缺血性卒中关联的证据有限,还涉及动脉粥样硬化以外的机制。近日,有研究人员利用已发表文献的汇总数据以及未发表的队列研究进行系统回顾和荟萃分析,以探索基于人群的前瞻性队列研究中循环IL-6水平与缺血性卒中发病风险的关系。

      遵循Prisma指南,研究人员系统地筛选了PubMed搜索引擎,从最初到2021年3月,进行基于人群的前瞻性队列研究,探索循环中IL-6水平与缺血性卒中发病风险之间的关系。将缺血性卒卒中险的关联估计与随机效应模型合并,并在剂量-反应荟萃分析中探索非线性效应。采用纽卡斯尔-渥太华量表(NOS)评估偏倚风险。使用漏斗图和修剪到填充的分析来评估出版偏倚。

  • 确定了11项研究(27,411人; 2,669例卒中事件)符合纳入标准。
  • 平均年龄为60.5岁,女性占54.8% 。整体而言,纳入研究的质素较高(中位数为8/9,四分差为7至9)。
  • 在荟萃分析中,循环对数转化IL-6水平的1个标准差增加与平均随访12.4年(RR 1.19; 95% CI 1.10-1.28)发生缺血性卒中的风险增加19% 相关。
  • 剂量-反应荟萃分析显示循环IL-6水平与缺血性卒中风险呈线性相关。
  • 在限于低偏倚风险的研究和完全调整人口和血管风险因素的研究中,只有适度的异质性,敏感性分析的结果是一致的。

  • 调整发表偏差后,结果也保持稳定。

      在社区居民中,较高的循环IL-6水平与较高的发生缺血性卒中的长期风险呈线性关系,与传统的血管危险因素无关。结合基因研究和临床试验的发现,这些结果为IL-6信号在缺血性卒中中的关键作用提供了额外的支持。

文献来源:Papadopoulos A, Palaiopanos K, Björkbacka H, et al. Circulating Interleukin-6 Levels and Incident Ischemic Stroke: A Systematic Review and Meta-analysis of Prospective Studies [published online ahead of print, 2021 Dec 30]. Neurology. 2021;10.1212/WNL.0000000000013274. doi:10.1212/WNL.0000000000013274

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-06-06 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-17 kzlchina
  6. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-17 ms5000000518166734

    学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-16 叶子12

    学习了,以前只知道CRP。现在多了一种

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1806494, encodeId=63191806494a1, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed Jul 13 04:22:12 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001689, encodeId=190220016891d, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 06 03:22:12 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893468, encodeId=5aba189346867, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 03 23:22:12 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948962, encodeId=77581948962e5, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 07 19:22:12 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273817, encodeId=c78312e381740, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1401364, encodeId=3300140136459, content=<a href='/topic/show?id=80e89e0479a' target=_blank style='color:#2F92EE;'>#长期风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97047, encryptionId=80e89e0479a, topicName=长期风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620617, encodeId=adb7162061e98, content=<a href='/topic/show?id=25a4e1714f0' target=_blank style='color:#2F92EE;'>#白细胞介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71714, encryptionId=25a4e1714f0, topicName=白细胞介素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1dc20143475, createdName=yxch43, createdTime=Mon Jan 17 13:22:12 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185077, encodeId=b81411850e705, content=学习学习学习学习学习学习学习学习学习学习学习学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Mon Jan 17 07:53:43 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184821, encodeId=5cdb11848214c, content=学习了,以前只知道CRP。现在多了一种, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/12/539233de2bda9b8c67d179a9bf6036a1.jpg, createdBy=d4a42010049, createdName=叶子12, createdTime=Sun Jan 16 13:01:29 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184791, encodeId=246b1184e91ee, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210303/66c17b62a9f144ea8281a5b0894d47e4/c6a5dc1e748547fbb2995fbdb3ecbb88.jpg, createdBy=5dee5415333, createdName=卜小布, createdTime=Sun Jan 16 11:34:28 CST 2022, time=2022-01-16, status=1, ipAttribution=)]
    2022-01-16 卜小布

    学习了

    0

相关资讯

Neurology:小儿卒中年龄是远期认知预后关键,幼年卒中(29天-6岁)影响极大

儿童缺血性卒中是一种罕见的事件,但伴随着认知和神经后遗症风险的增加。卒中年龄是卒中预后的一个重要因素,并影响长期认知结果,与病变大小和病变位置无关。儿童早期卒中后,儿童长期认知功能改变的风险极大

Stroke:这7种药物可能诱发缺血性卒中,谨慎使用!

药物相关性缺血性脑卒中,是指因药物使用导致血管内皮功能障碍、凝血改变或纤维蛋白溶解等异常,进而导致缺血性脑卒中的发生。

JAMA:两个简单量表指导PFO闭合术的决策

在18-60岁青壮年和中年人缺血性卒中中,卵圆孔未闭(PFO)相关性卒中占10%。预防PFO相关缺血性卒中患者复发性卒中的治疗策略包括抗血栓治疗或经皮PFO封堵,每种治疗策略都在实践指南中得到认可。

Stroke:缺血性卒中后静脉溶栓与降低痴呆发生率的关系

首次缺血性卒中后溶栓治疗与痴呆发生率降低独立相关。在评估缺血性卒中患者溶栓的风险/益处时,应将事件性痴呆视为相关结局。

Stroke:缺血性卒中后,血脑屏障破坏和低灌注,和脑水肿相关

再灌注治疗后梗死区的BBB破坏和持续的低灌注与占位性脑水肿有关

Stroke:缺血性卒中,有哪些心源性的风险因素

现有的遗传数据并不支持心脏特征对已知临床危险因素以外的卒中风险的实质性影响

拓展阅读

Neurology:老年癫痫、血管危险因素和认知能力下降的关系

一些VRFs与老年人认知能力下降的关联在有癫痫的情况下更强

Neurology:老年人癫痫、血管危险因素和认知功能减退:心血管健康研究

个体血管危险因子(VRF)与认知轨迹的关联是否因癫痫流行的存在而不同?在癫痫存在的情况下,一些VRF与老年人认知能力下降的相关性更强,这表明需要更多地关注血管保护,以保护患有癫痫的老年人的大脑健康。

Neurology:确定痴呆的血管危险因素和中老年痴呆风险预测:Framingham心脏研究

血管危险因素与痴呆之间的关联因年龄而异,这使得痴呆风险预测规则对不同年龄个体的普适性具有挑战性。近日,一项发表在Neurology上的研究确定了年龄特定的痴呆症风险评分中包含的最重要的血管危险因素。

JAMA Neurol:针对血管危险因素的干预预防痴呆症效果如何?

生活方式干预对预防痴呆症的潜在益处的大小可能比队列研究预测的要小,正如数据现在在老年人身上所显示的那样。对于从中年到晚年的更广泛的年龄段,尽管因果关系尚不清楚,可能存在更大的机会窗口。

JAHA:老年人血管危险因素和APOE基因型与血管周间隙的关系

这项研究提供了有限的证据支持老年人磁共振成像上PVS与传统血管危险因素之间存在相关性。直立性低血压与APOEε4携带者脑叶PVS的关联表明,脑叶PVS可能是淀粉样蛋白相关小血管疾病的标志。

SCI REP:中国卒中亚型和血管危险因素的变化趋势!

总之,卒中亚型的比例发生了显著变化。需要加强降压治疗来控制ICH、SAH和SVD缺血性卒中的发生率。提高IS的病因学检测及降脂治疗是有效的,心源性栓塞的检测也进一步加强。

缺血性脑卒中(大动脉粥样硬化型)治未病干预指南

北京中医药大学东方医院 · 2023-08-30

缺血性脑卒中复发预防的最佳证据总结

广州医科大学护理学院 · 2023-06-10

缺血性脑卒中患者高血糖管理的最佳证据总结

华中科技大学同济医学院附属同济医院神经内科 · 2023-02-10